Ajooni Biotech Share Price

Ajooni Biotech Limited, together with its subsidiaries, is an Indian animal healthcare solutions company primarily engaged in the manufacturing, processing, and supplying of cattle feed, nutrients related to cattle feed, and animal health care supplements. The company also manufactures and sells cattle feed under its own brand name ‘Autus Animal Healthcare’. The company operates through a single segment: Pharmaceuticals. It offers a range of products including cattle feed chips, camel and pig feed, cotton oil cakes, mustard oil cakes, and feed supplements. The Ajooni Biotech share price today on the NSE and BSE is a reflection of how market participants respond to a company’s performance and broader business developments within its industry. It captures the sentiment of the investors based on financial results, operational updates, macroeconomic factors, and trends specific to sectors. Movements in the share price͏ reveal how the market evaluates the company’s current position and its future prospects, making ͏it a key indicator of market perception across various industries.

Market sentiment around the Ajooni Biotech stock price often mirrors shifts in livestock demand, raw material prices (soybean, maize), and investor views on the small-cap animal health sector’s growth prospects. Factors such as the pace of new product introductions, competitive intensity from domestic players, raw material cost inflation, and changing regulatory frameworks influence near-term market valuation and medium-term earnings forecasts. All these factors must be closely monitored to have an idea about theAjooni Biotechstock price movements.

Ajooni Biotech live share price provides real-time information about the last price traded, bid price, ask price, and volume traded. These indicators represent trading activity and liquidity and the reaction of investors to corporate announcements, quarterly results, and sector news. Constant ͏monitoring ofAjooni Biotechlive price helps observe short-term price fluctuations and understand how the stock is moving in relation to the broader market.

Furthermore, monitoring theAjooni Biotechshare͏ price today helps investors understand real-time market sentiment, price volatility, and trading behaviour. It allows market participants to evaluate short-term performance, identifypossible entry or exit points, and respond to news, quarterly results or sector trends that may affect the company’s valuation and overall investment outlook.

Ajooni Biotech Limited Company Fundamentals

a. Company Background

Ajooni Biotech Limited is an Indian animal healthcare solutions company engaged in the manufacturing, processing, and supplying of cattle feed, nutrients related to cattle feed, and animal health care supplements. It was originally incorporated as a private limited company under the name ‘Ajooni Biotech Private Limited’ at Chandigarh on February 17, 2010, under the provisions of the Companies Act, 1956, vide Certificate of Incorporation issued by the Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh. The company was converted into a public limited company and changed its name to ‘Ajooni Biotech Limited’. The company has its registered office at D-118 Industrial Area, Phase-7, Mohali, Punjab, India. Ajooni Biotech is engaged in manufacturing, producing, processing and supplying of cattle feed, nutrients related to cattle feed and manufacturing & production of animal health care supplements. The company is registered with the Department of Industries, Govt. of Punjab as a Small Scale Industry (SSI) and also registered with the Department of Dairy Development, Govt of Punjab. The company also manufactures cattle feed and supplements under its own brand name ‘Autus Animal Healthcare’. For marketing its own brand, it has a strong professional team covering the areas of Punjab, Haryana, Uttar Pradesh, Rajasthan and Jammu and Kashmir. The company also has an agreement with Patanjali for the manufacturing and distribution of cattle feed and supplements under the brand name of Patanjali. It operates within India’s growing animal healthcare and feed industry, driven by rising livestock population, increasing dairy demand, and government initiatives to promote animal husbandry.

b. Product Lines

• Cattle feed chips

• Camel feed

• Pig feed

• Cotton oil cakes

• Mustard oil cakes

• Feed supplements

• Animal health care supplements

• Compounded animal feed products including Diamond Wonder, Nurture Calf Starter, Winner, Hiffer/Grower, Milk Booster, and Eco

• Patanjali brand products including Patanjali Samvriddhi, Patanjali Garbhanjali, Patanjali Batisa-Pro

c. Company Revenue Model

• Primary revenue from the manufacturing and sale of cattle feed and animal feed supplements to dairy farmers and agricultural customers

• Revenue from the sale of animal health care supplements

• Revenue from contract manufacturing for Patanjali under the brand name of Patanjali

• Income from the sale of by-products including oil cakes

• Revenue from the ‘Autus Animal Healthcare’ brand products

• Revenue from distribution through a strong professional team covering multiple states

• Income from supply agreements including with National Dairy Development Board (NDDB) Dairy Services

d. Geographic Presence

• Registered office located in Mohali, Punjab, India

• Strong domestic presence serving customers across Punjab, Haryana, Uttar Pradesh, Rajasthan, and Jammu and Kashmir

• Primary operations concentrated in North India with a focus on the dairy farming belt

• Limited international presence through exports

• Delivery model leverages a combination of own brand (Autus Animal Healthcare) and contract manufacturing (Patanjali)

e. Key Milestones

• 2010: Incorporated as Ajooni Biotech Private Limited on February 17, 2010

• 2017: Initial Public Offering (IPO) on NSE SME platform priced at ₹30 per equity share with face value of ₹10

• 2018: Shares listed on NSE SME on January 2, 2018

• 2022: Migrated to the main board of NSE in May 2022

• 2025: Reported net profit of ₹3.37 crore in FY2025, up 56.02% from ₹2.16 crore in FY2024

• 2025: Net profit rose 126.03% to ₹1.65 crore in the December 2025 quarter

f. Industry Perspective: Animal Feed and Healthcare Industry in India

Ajooni Biotech operates in the global and Indian animal feed and healthcare industry. Globally, the animal feed market continues to expand driven by rising meat and dairy consumption, increasing livestock population, and growing awareness about animal nutrition. In India, the animal feed industry is one of the fastest-growing agricultural segments. The Indian animal feed market size reached INR 1,110.0 billion (approximately USD 13.3 billion) in 2024 and is projected to reach INR 2,025.1 billion (approximately USD 24.3 billion) by 2033, growing at a CAGR of 6.9% during 2025-2033. India has the largest cattle population in the world, which is escalating the demand for animal feed across the country. The India Animal Health Market was valued at USD 1.97 billion in 2024 and is projected to reach USD 4.21 billion by 2030, rising at a CAGR of 13.90%. The India veterinary healthcare market size is USD 1.62 billion in 2025 and is projected to reach USD 2.45 billion in 2030, reflecting an 8.73% CAGR during the forecast period. The Indian feed additives market is expected to grow at a CAGR of 7.00% in the forecast period of 2025-2034. India’s livestock population in 2025 is estimated at 591 million animals, comprising about 265 million cattle, 85 million buffaloes, 166 million sheep and goats, 28 million pigs, and 97 million poultry. The livestock sector provides employment to about 8.8% of the population in India. Key growth drivers include rising milk production (India is the world’s largest milk producer), government initiatives such as the National Livestock Mission (NLM) with a total outlay of ₹2,300 crore, and increasing awareness about animal healthcare. The National Livestock Mission provides 50% capital subsidy for feed and fodder development. However, the industry faces challenges including raw material price volatility, fragmented unorganized sector, and supply chain inefficiencies. The industry outlook remains positive, supported by sustained government support, rising dairy demand, and increasing livestock population.

Ajooni Biotech Limited Stock Market Presence: Listings & Index Representation

Ajooni Biotech Limited is actively traded on India’s principal equity markets, with its shares listed on the National Stock Exchange of India (NSE) under the symbol AJOONI and on the Bombay Stock Exchange (BSE) with the scrip code 535040. The ISIN number of the company’s equity shares is INE820Y01021. The face value of the equity shares is ₹2 per share. Its listing on both exchanges ensures that the Ajooni Biotech price is accessible to a wide investor base, encompassing both retail and institutional market participants. The company was listed on the NSE SME platform on January 2, 2018, following its IPO, and later migrated to the main board of NSE in May 2022. The company forms part of several benchmark indices that represent broad market segments. Ajooni Biotech is included in indices such as the BSE SmallCap and Nifty Microcap 250. These index participations signal the company’s relevance within market categories that attract both active and passive investment flows. Being represented in these indices enhances the visibility and liquidity of the Ajooni Biotech stock price, as index tracking funds and exchange traded strategies often adjust allocations in line with constituent revisions. It also allows investors to benchmark the company’s stock performance relative to broader market trends and peer groups, facilitating cross sectional comparisons within India’s animal healthcare landscape. The inclusion of Ajooni Biotech in these indices reflects its market capitalisation and trading depth, which are key factors market participants consider when evaluating long term investment prospects and the responsiveness of the stock price to corporate and industry developments.

Ajooni Biotech Limited Stock Performance and Share Price History

The Ajooni Biotech share price has displayed extreme volatility since its listing on the NSE SME platform in January 2018, shaped by the company’s financial performance, conversion from SME to main board, and broader market trends. The Ajooni Biotech share price reached a 52-week high of ₹6.60 on June 24, 2025, and a 52-week low of ₹3.55, indicating a wide trading range and substantial price fluctuations. The Ajooni Biotech share price was trading at approximately ₹4.05-₹4.29 in April 2026, down from its 52-week high. The Ajooni Biotech share price has delivered a 1-year return of approximately -31.68% to -49.28% according to various sources, significantly underperforming the broader market. The Ajooni Biotech share price has shown a 3-year return of -37.4% to -5.69% depending on the measurement period, and a 5-year return of -14.49%. The Ajooni Biotech share price has also delivered a 10-year return that has been volatile, with the company’s financial track record indicating average quality.

The Ajooni Biotech stock price has been particularly responsive to quarterly earnings releases and corporate announcements. When the company reported net profit of ₹1.65 crore in the December 2025 quarter, up 126.03% from ₹0.73 crore in the previous quarter, the Ajooni Biotech stock price showed a positive reaction. The Ajooni Biotech share price has shown a pattern of strong positive momentum following strong earnings reports, while periods of weak financial results or market consolidation have contributed to declines in the Ajooni Biotech stock price. The Ajooni Biotech share price delivered a 1-year total return of approximately -30.28% according to MarketsMojo, underperforming the broader market. The Ajooni Biotech share price has shown a YTD return that has fluctuated, while the 1-month return was approximately 26.25% in February 2026 and -12.3% in January 2026. The Ajooni Biotech share price has been influenced by corporate developments including the migration from SME to main board of NSE in May 2022, the agreement with National Dairy Development Board (NDDB) Dairy Services for supply of cattle feed, and the company’s consistent financial turnaround. The Ajooni Biotech share price has shown average weekly volatility of approximately 7-10%, which is higher than the industry average.

The Ajooni Biotech share price has a 10-year aggregate net profit that has shown improvement in recent years, with net profit increasing to ₹3.37 crore in FY2025 from ₹2.16 crore in FY2024. The Ajooni Biotech share price has also delivered a 10-year return that has been volatile. Comprehending these patterns in the Ajooni Biotech share price is instrumental for investors seeking to contextualise long term performance trends vis à vis short term price dynamics, as the Ajooni Biotech stock price movements illustrate how industry fundamentals, raw material price cycles, government policies, and investor expectations converge in market pricing.

Ajooni Biotech Limited Investor Relevance and Role in Portfolio

Ajooni Biotech holds a challenging position for portfolio investors who seek exposure to the Indian animal healthcare sector with a focus on cattle feed and supplements. The company’s diversified product portfolio across cattle feed, oil cakes, and animal health supplements aligns it with investment strategies that value both domestic dairy consumption growth and agricultural sector development. The Ajooni Biotech share price often mirrors how these themes resonate with investor portfolios, whereby both thematic and sector specific funds monitor livestock population indicators and raw material price metrics when evaluating allocation decisions.

Institutional stakeholders play a minimal role in Ajooni Biotech’s ownership profile. The promoters held approximately 26.89% of the company as of December 2025, showing a stable trend with no change from previous quarters. The promoter with the highest holding is Jasjot Singh at 16.82%. Mutual funds do not hold any stake in the company as of December 2025, with mutual funds holding 0.00%. Foreign Institutional Investors (FIIs) hold 0.00% of the company as of December 2025, down from 0.18% in December 2024. Domestic Institutional Investors (DIIs) hold 0.00% of the company. Retail and other shareholders hold approximately 73.11% of the company. Overall institutional holding in the company stands at approximately 0.00% as of December 2025. The company’s promoters have not pledged any significant portion of their shares.

Based on data, the beta for Ajooni Biotech has been recorded at 1.33 , 1.24-1.28 , and 1.0374 (Financial Times), indicating that the stock has exhibited higher volatility than the broader market over extended periods. The 5-year beta is 0.29, suggesting lower long-term volatility. The 1-year beta is -30.28% return basis. The mean beta across different time frames is approximately 1.0, with standard deviations varying accordingly\

The Ajooni Biotech share price has shown periods of heightened responsiveness to sector-specific news, quarterly earnings releases, and raw material price movements. The Ajooni Biotech share price reflects that the company’s position in the small-cap animal healthcare sector may result in moderate to high price fluctuations. The Ajooni Biotech stock price is thus viewed as a speculative opportunity within a portfolio context with varying volatility characteristics depending on the time frame.

Ajooni Biotech Limited Sectoral Relevance and Peer Positioning

The sector relevance of Ajooni Biotech is anchored in its role within the broader Indian animal feed and healthcare industry, where it competes with other diversified feed and supplement manufacturing companies. As part of this industry, the company’s strategic positioning connects cattle feed manufacturing, animal health supplements, and oil cake production that serve multiple agricultural segments. Competitors in adjacent segments include companies such as Godrej Agrovet Limited, Avanti Feeds Limited, Mukka Proteins Limited, KSE Limited, and Waterbase Limited. Larger players such as Godrej Agrovet and Avanti Feeds have larger scale and diversified product portfolios, though Ajooni Biotech competes directly in the cattle feed and supplement segment. Other competitors include Mukka Proteins (animal protein company focused on animal feed ingredients), Magronic Contrivance, and National Dairy Development Board. Firms with parallels in either manufacturing scale or distribution relationships are often referenced when evaluating relative performance and operational positioning within the sector.

In valuation terms, factors like the Ajooni Biotech P/E ratio tend to reflect narrative shifts in earnings expectations and investor confidence relative to these peers. The Ajooni Biotech P/E ratio stood at approximately 20.96 times as of March 2025, compared to Godrej Agrovet at 31.92 times and Avanti Feeds at 31.92 times. The P/B ratio of Ajooni Biotech is 0.81 times as of April 2026, with a 52-week low of 4 and a 52-week high of 7. The Ajooni Biotech earnings history over the past five years has shown a pattern of consistent improvement. Net profit increased from ₹2.16 crore in FY2024 to ₹3.37 crore in FY2025, up 56.02% year-on-year. For the December 2025 quarter, net profit rose 126.03% to ₹1.65 crore from ₹0.73 crore in the previous quarter. Total revenue for the quarter ended December 2025 stood at ₹31.91 crore, up 4.25% from the previous quarter and 24.20% year-on-year. The Ajooni Biotech EPS narrative has followed a similar pattern of improvement. EPS (TTM) has been recorded at approximately ₹0.16 to ₹0.20 over different periods, with a current TTM EPS of approximately ₹0.20. Basic EPS has shown improvement from previous years. The Ajooni Biotech market cap has shown a pattern of significant fluctuation over the past decade. Ajooni Biotech market cap decreased from approximately ₹1.34 billion in December 2024 to approximately ₹828.49 million in February 2026, after reaching a peak of ₹1.34 billion in December 2024 with 138.68% growth. The market cap further decreased to approximately ₹742.37 million in December 2025, down 44.53%. The current market cap stands at approximately ₹73.89-₹89.05 crore as of April 2026.

Over the last ten years, Ajooni Biotech market cap has shown a pattern of significant fluctuation. The company’s market cap decreased from approximately ₹1.34 billion in December 2024 to approximately ₹828.49 million in February 2026. The market cap has shown a 10-year aggregate net profit that has improved in recent years, with net profit reaching ₹3.37 crore in FY2025. The current market cap stands at approximately ₹73.89-₹89.05 crore, having ranged between lower levels and its current value over the past decade since IPO.

Ajooni Biotech earnings, in terms of net profit, have exhibited a pattern of consistent improvement over recent years. Net profit increased from ₹2.16 crore in FY2024 to ₹3.37 crore in FY2025, up 56.02% year-on-year. For the December 2025 quarter, net profit rose 126.03% to ₹1.65 crore from ₹0.73 crore in the previous quarter. Total revenue for the December 2025 quarter stood at ₹31.91 crore, up 24.20% year-on-year. The company’s operating profit rose by 224.33% in the last financial year.

Ajooni Biotech EPS history over the past decade has shown a pattern of improvement. EPS (TTM) has been recorded at approximately ₹0.16 to ₹0.20 over different periods, with a current TTM EPS of approximately ₹0.20. Basic EPS has shown improvement from previous years, reflecting the company’s enhanced profitability on a per-share basis, supported by strong net profit growth.

Ajooni Biotech P/E ratio history has shown a pattern of variation, fluctuating between moderate and elevated levels over the past decade. The P/E ratio stood at approximately 20.96 times as of March 2025, compared to Godrej Agrovet at 31.92 times. The P/E ratio has ranged from approximately 19.73 to 22.03 over different periods. This valuation reflects that investor expectations remain anchored to the company’s earnings improvement trajectory and market position in the animal feed segment.

Summary

Ajooni Biotech is a small-cap Indian animal healthcare company listed on the NSE, where the Ajooni Biotech share price reflects livestock demand cycles, raw material price trends, and competitive dynamics within the animal feed sector. Its representation in stock indices supports market visibility, while investor interest is heavily constrained by thin promoter holding, minimal institutional interest, and high retail ownership. Within the sector, the company’s competitive context and earnings dynamics provide key perspectives on its role in the Indian animal feed market.